
Millendo Therapeutics, Inc. MLND
Millendo Therapeutics, Inc. EV/EBITDA Ratio | MLND
Annual EV/EBITDA Ratio Millendo Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1.01 | 1.23 | 2.67 | 0.292 | 0.554 | 0.467 | -1.25 | 0.275 | 0.857 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.67 | -1.25 | 0.679 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Monopar Therapeutics
MNPR
|
-20.5 | $ 71.42 | -3.16 % | $ 529 M | ||
|
BridgeBio Pharma
BBIO
|
-30 | $ 78.67 | 0.95 % | $ 15.1 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
8.17 | $ 7.53 | -1.38 % | $ 1.58 B | ||
|
Bicycle Therapeutics plc
BCYC
|
0.703 | $ 3.68 | -2.39 % | $ 255 M | ||
|
Coherus BioSciences
CHRS
|
-1.86 | $ 0.64 | -21.66 % | $ 75 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-316 | $ 27.45 | 4.77 % | $ 3.49 B | ||
|
Cellectis S.A.
CLLS
|
-15.8 | $ 1.12 | -0.45 % | $ 112 M | ||
|
BeyondSpring
BYSI
|
-12.6 | $ 0.6 | -2.21 % | $ 24.7 M | ||
|
Alkermes plc
ALKS
|
19.2 | $ 46.48 | 0.67 % | $ 7.66 B | ||
|
Altimmune
ALT
|
-3.49 | $ 1.94 | -8.51 % | $ 171 M | ||
|
Cardiff Oncology
CRDF
|
-2.37 | $ 0.79 | -0.77 % | $ 52.8 M | ||
|
Citius Pharmaceuticals
CTXR
|
-1.5 | $ 0.5 | -5.43 % | $ 5.53 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-0.593 | $ 9.41 | -0.84 % | $ 258 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
50 | $ 49.04 | -0.41 % | $ 6.56 B | ||
|
Atara Biotherapeutics
ATRA
|
3.26 | $ 8.18 | -0.73 % | $ 103 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
37 | $ 16.3 | -1.93 % | $ 2.19 B | ||
|
Cullinan Management
CGEM
|
-3.52 | $ 11.34 | -3.32 % | $ 683 M | ||
|
BioNTech SE
BNTX
|
-12.2 | $ 87.2 | -0.36 % | $ 21.1 B | ||
|
Collegium Pharmaceutical
COLL
|
38.8 | $ 24.47 | -0.97 % | $ 775 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-1.4 | $ 3.95 | 12.07 % | $ 52.6 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-29.5 | $ 1.21 | -11.68 % | $ 55.3 M | ||
|
AnaptysBio
ANAB
|
45.1 | $ 48.4 | 0.9 % | $ 1.4 B | ||
|
Assembly Biosciences
ASMB
|
-25.1 | $ 21.33 | -2.11 % | $ 239 M | ||
|
Adagene
ADAG
|
-8.38 | $ 2.02 | -4.95 % | $ 119 M | ||
|
Benitec Biopharma
BNTC
|
-7.59 | $ 9.31 | -5.67 % | $ 433 M | ||
|
Denali Therapeutics
DNLI
|
-4.29 | $ 19.85 | -2.36 % | $ 3.43 B | ||
|
Amarin Corporation plc
AMRN
|
-125 | $ 11.75 | 0.09 % | $ 4.88 B | ||
|
ImmuCell Corporation
ICCC
|
15.7 | $ 10.4 | 1.76 % | $ 93.9 M | ||
|
Editas Medicine
EDIT
|
-1.41 | $ 2.5 | -9.09 % | $ 222 M | ||
|
Agios Pharmaceuticals
AGIO
|
-3.53 | $ 31.77 | 1.23 % | $ 1.84 B | ||
|
Cue Biopharma
CUE
|
-0.704 | $ 18.89 | -6.21 % | $ 1.79 B | ||
|
Equillium
EQ
|
-3.87 | $ 1.45 | -3.33 % | $ 83.1 M | ||
|
Black Diamond Therapeutics
BDTX
|
10.5 | $ 1.6 | -14.05 % | $ 91 M | ||
|
Abeona Therapeutics
ABEO
|
-2.69 | $ 2.46 | -3.35 % | $ 130 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
36 | $ 18.13 | 9.85 % | $ 3.05 B | ||
|
Atossa Therapeutics
ATOS
|
-0.367 | $ 2.21 | 3.76 % | $ 19 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
-22.4 | - | -7.31 % | $ 49 M | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
-6.28 | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
-3.2 | $ 1.51 | -9.88 % | $ 192 M | ||
|
Harmony Biosciences Holdings
HRMY
|
5.42 | $ 33.57 | -0.62 % | $ 1.93 B | ||
|
Ardelyx
ARDX
|
-49.8 | $ 3.0 | 2.39 % | $ 723 M | ||
|
Akebia Therapeutics
AKBA
|
19.9 | $ 0.54 | 1.8 % | $ 139 M | ||
|
Alector
ALEC
|
-2.95 | $ 2.54 | 3.05 % | $ 262 M | ||
|
ALX Oncology Holdings
ALXO
|
-1.27 | $ 1.11 | -13.62 % | $ 59.6 M | ||
|
Amneal Pharmaceuticals
AMRX
|
8.92 | $ 21.39 | 0.52 % | $ 6.7 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-9.75 | $ 5.45 | 2.16 % | $ 397 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-22.4 | $ 3.8 | 2.15 % | $ 728 M | ||
|
Agenus
AGEN
|
-9.32 | $ 7.02 | -1.82 % | $ 209 M | ||
|
AbCellera Biologics
ABCL
|
-6.16 | $ 12.44 | -0.52 % | $ 3.72 B | ||
|
Artelo Biosciences
ARTL
|
-0.327 | $ 2.14 | 2.01 % | $ 405 K |